AKTS Financials

Income Statement
MetricQ2 2026Q1 2026
Revenue
3.4M
+4.9%
3.2M
Cost of Revenue
0
0
Gross Profit
3.4M
+4.9%
3.2M
Operating Expenses
32.3M
+24.5%
25.9M
R&D
25.3M
+26.2%
20.0M
SG&A
7.0M
+18.8%
5.9M
Operating Income
-28899000
-27.3%
-22706000
EBITDA
-28020000
-27.1%
-22054000
Net Income
-24144000
-31.8%
-18325000
EPS (Basic)
$-0.44
-15.8%
$-0.38
EPS (Diluted)
$-0.44
-15.8%
$-0.38
Shares (Diluted)
55.3M
+13.7%
48.6M
Aktis Oncology (AKTS) — Financials